Ridgely Fisk Green1, Marie T Kumerow2, Juan L Rodriguez2, Siobhan Addie3, Sarah H Beachy3, Laura Senier4. 1. Carter Consulting, Inc. and Office of Genomics and Precision Public Health, Office of Science, Centers for Disease Control and Prevention, Atlanta, Georgia, USA, grf1@cdc.gov. 2. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 3. National Academies of Sciences, Engineering, and Medicine, Washington, District of Columbia, USA. 4. Department of Sociology & Anthropology and Department of Health Sciences, Northeastern University, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: To show how state health agencies can plan and evaluate activities to strengthen the evidence base for public health genomics, we mapped state cancer genomics activities to the Doyle et al. [Genet Med. 2018;20(9):995-1003] implementation science outcome framework. METHODS: We identified state health agency activities addressing hereditary breast and ovarian cancer and Lynch syndrome by reviewing project narratives from Centers for Disease Control and Prevention Cancer Genomics Program funding recipients, leading discussions with state health agencies, and conducting an environmental scan. RESULTS: State health agencies' cancer genomics activities included developing or adding to state surveillance systems, developing educational materials, bidirectional reporting, promoting health plan policy change, training providers, and promoting recommendations and standards. To address health disparities, programs have tracked group differences, developed culturally appropriate educational materials, and promoted access to services for underserved populations. CONCLUSION: State health agencies can use the Doyle et al. [Genet Med. 2018;20(9):995-1003] performance objectives and outcome measures to evaluate proposed and ongoing activities. By demonstrating whether activities result in improved outcomes, state health agencies can build the evidence for the implementation of cancer genomics activities.
OBJECTIVE: To show how state health agencies can plan and evaluate activities to strengthen the evidence base for public health genomics, we mapped state cancer genomics activities to the Doyle et al. [Genet Med. 2018;20(9):995-1003] implementation science outcome framework. METHODS: We identified state health agency activities addressing hereditary breast and ovarian cancer and Lynch syndrome by reviewing project narratives from Centers for Disease Control and Prevention Cancer Genomics Program funding recipients, leading discussions with state health agencies, and conducting an environmental scan. RESULTS: State health agencies' cancer genomics activities included developing or adding to state surveillance systems, developing educational materials, bidirectional reporting, promoting health plan policy change, training providers, and promoting recommendations and standards. To address health disparities, programs have tracked group differences, developed culturally appropriate educational materials, and promoted access to services for underserved populations. CONCLUSION: State health agencies can use the Doyle et al. [Genet Med. 2018;20(9):995-1003] performance objectives and outcome measures to evaluate proposed and ongoing activities. By demonstrating whether activities result in improved outcomes, state health agencies can build the evidence for the implementation of cancer genomics activities.
Authors: L Brannon Traxler; Monique L Martin; Alice S Kerber; Cecelia A Bellcross; Barbara E Crane; Victoria Green; Roland Matthews; Nancy M Paris; Sheryl G A Gabram Journal: Ann Surg Oncol Date: 2014-07-22 Impact factor: 5.344
Authors: Muin J Khoury; Michael S Bowen; Wylie Burke; Ralph J Coates; Nicole F Dowling; James P Evans; Michele Reyes; Jeannette St Pierre Journal: Am J Prev Med Date: 2011-04 Impact factor: 5.043
Authors: Debra Lochner Doyle; Mindy Clyne; Juan L Rodriguez; Deborah L Cragun; Laura Senier; Georgia Hurst; Kee Chan; David A Chambers Journal: Genet Med Date: 2018-01-04 Impact factor: 8.822